Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Prevention of Fracture in Postmenopausal Women
Radius Health, Inc.2,463 participantsApr 2011 to Oct 2014
Osteoporosis · Postmenopausal Osteoporosis
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog Chonluten (EDG) | Synthetic analog Abaloparatide (Tymlos) | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Synthetic analog | |
| Area | Recovery and repair | Recovery and repair | |
| Evidence | |||
| Amount of evidence | 1 | 878 | |
| Evidence level | Results from lab studies only | Has results from studies in people | |
| Safety | |||
| Safety results | No safety results | 84 (70 in people) | |
| Status | |||
| Approval | Not recorded | ||
| Sport (WADA) | |||
| Registered trials | None registered | 21 · 5 active4 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
The FDA label for Tymlos says: “A synthetic PTH-related peptide analog approved for osteoporosis in selected patients”
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Chonluten (EDG) | Abaloparatide (Tymlos) |
|---|---|---|
| Inflammation markersImmune and inflammation | 11 | 211 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
No registered trial that tests Chonluten (EDG) found in ClinicalTrials.gov.
Top 3 of 21 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Radius Health, Inc.2,463 participantsApr 2011 to Oct 2014
Osteoporosis · Postmenopausal Osteoporosis
Radius Health, Inc.511 participants5 Aug 2019 to 9 Nov 2021
Postmenopausal Osteoporosis
Radius Health, Inc.228 participants3 May 2018 to 8 Sept 2021
Osteoporosis · Osteoporosis, Age-Related · Osteoporosis Localized to Spine · Age Related Osteoporosis · Osteoporosis Senile · Osteoporosis of Vertebrae
4 more mention it but do not test it. They only measure it or name it in their text.